[Application of a novel intracorporeal combined pneumatic and ultrasonic lithotriptor (CQS-01) in percutaneous nephrolithotomy]

To evaluate the safety and efficacy of a new intracorporeal pneumatic and ultrasonic lithotriptor (CQS-01) in percutaneous nephrolithotomy (PNL).

In the study, 408 patients with renal or upper ureteral stones suitable for PNL treatment were treated with CQS-01 ultrasonic and pneumatic lithotripter. Their stone position: Single side 368 patients and bilaterial 40 patients. Simple kidney stones: 312 patients, combined ureteral and kidney 42 patients, and simple ureteral stones 54 patients. Stone burden: staghorn stone: 95 patients. All the patients were followed up for 1 week post-operation. The data were collected and analyzed with regard to stone burden, postoperative stone clearance rate, operation time, occurrence rate of adverse events.

The postoperative stone-free rate was 91.2% and the residual stone rate 8.8%; The mean operation time was (90.5±68.0) min; There were 6 patients (1.5%) who received selective renal artery embolism because of bleeding after operation. One patient had severe urinary infection and no other severe complications happened.

CQS-01 ultrasonic and pneumatic lithotriptor is safe and effective in PNL, and suitable for clinical application.